$CELC
Celcuity Inc. Stock $celc

$celc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011549 Filed on March 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.846M	$1.648M	$5.636M
YoY Change	45.49%	59.21%	37.42%
% of Gross Profit
Research & Development	$20.65M	$18.08M	$60.59M
YoY Change	83.07%	70.51%	71.71%
% of Gross Profit
Depreciation & Amortization	$29.56K	$32.77K	$142.8K
YoY Change	-32.73%	-33.04%	-32.31%
% of Gross Profit
Operating Expenses	$22.49M	$19.73M	$66.23M
YoY Change	79.27%	69.51%	68.14%
Operating Profit	-$22.49M		-$66.23M
YoY Change	79.27%		68.14%
Interest Expense	$1.401M	$880.8K	$5.326M
YoY Change	12.78%	1422.3%	152.9%
% of Operating Profit
Other Income/Expense, Net	$881.4K		$2.451M
YoY Change	44.7%		-350.39%
Pretax Income	-$21.61M	-$18.85M	-$63.78M
YoY Change	81.03%	62.75%	57.99%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$21.61M	-$18.85M	-$63.78M
YoY Change	81.03%	62.75%	57.99%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.64		-$2.69
Diluted Earnings Per Share	-$0.64	-$0.65	-$2.69
COMMON SHARES
Basic Shares Outstanding	30.45M shares	24.20M shares	23.68M shares
Diluted Shares Outstanding	33.61M shares		23.68M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$177.7M	$180.6M	$180.6M
YoY Change	12.82%	7.12%	7.12%
Cash & Equivalents	$31.21M	$30.66M	$30.66M
Short-Term Investments	$146.4M	$149.9M	$149.9M
Other Short-Term Assets	$9.861M	$10.01M	$9.202M
YoY Change	49.79%	56.39%	43.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$187.5M	$190.6M	$190.6M
YoY Change	14.27%	8.79%	8.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$306.0K	$228.8K	$628.8K
YoY Change	37.02%	-12.11%	24.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$657.9K	$628.8K	$628.8K
YoY Change	-15.14%	24.13%	24.13%
TOTAL ASSETS
Total Short-Term Assets	$187.5M	$190.6M	$190.6M
Total Long-Term Assets	$657.9K	$628.8K	$628.8K
Total Assets	$188.2M	$191.2M	$191.2M
YoY Change	14.14%	8.83%	8.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.277M	$5.077M	$5.077M
YoY Change	105.33%	93.25%	93.24%
Accrued Expenses	$11.24M	$8.927M	$2.647M
YoY Change	269.63%	119.86%	32.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$16.70M	$14.19M	$14.19M
YoY Change	187.57%	106.19%	106.19%
LONG-TERM LIABILITIES
Long-Term Debt	$37.57M	$37.04M	$37.04M
YoY Change	5.89%	5.87%	5.87%
Other Long-Term Liabilities	$182.1K	$225.9K	$225.9K
YoY Change	-49.97%	270.36%	270.36%
Total Long-Term Liabilities	$37.75M	$37.26M	$37.26M
YoY Change	5.32%	6.33%	6.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.70M	$14.19M	$14.19M
Total Long-Term Liabilities	$37.75M	$37.26M	$37.26M
Total Liabilities	$54.44M	$51.45M	$51.45M
YoY Change	30.72%	22.72%	22.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$181.7M	-$160.1M
YoY Change	67.86%	66.23%
Common Stock	$30.77K	$25.51K
YoY Change	40.26%	17.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$133.7M	$139.8M	$139.8M
YoY Change
Total Liabilities & Shareholders Equity	$188.2M	$191.2M	$191.2M
YoY Change	14.14%	8.83%	8.83%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$21.61M	-$18.85M	-$63.78M
YoY Change	81.03%	62.75%	57.99%
Depreciation, Depletion And Amortization	$29.56K	$32.77K	$142.8K
YoY Change	-32.73%	-33.04%	-32.31%
Cash From Operating Activities	-$17.07M	-$18.53M	-$53.81M
YoY Change	32.64%	95.5%	49.44%
INVESTING ACTIVITIES
Capital Expenditures	$89.68K	$37.64K	$97.64K
YoY Change	1183.47%	-66.41%	-38.5%
Acquisitions
YoY Change
Other Investing Activities	$3.626M	-$41.18M	-$4.911M
YoY Change	-83.42%	-71.38%	-96.59%
Cash From Investing Activities	$3.536M	-$41.22M	-$5.008M
YoY Change	-83.83%	-71.37%	-96.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$14.08M	64.66M	$64.91M
YoY Change	20627.36%	-46.36%	-46.05%
NET CHANGE
Cash From Operating Activities	-$17.07M	-18.53M	-$53.81M
Cash From Investing Activities	$3.536M	-41.22M	-$5.008M
Cash From Financing Activities	$14.08M	64.66M	$64.91M
Net Change In Cash	$552.0K	4.911M	$6.091M
YoY Change	-93.91%	-114.92%	-110.2%
FREE CASH FLOW
Cash From Operating Activities	-$17.07M	-$18.53M	-$53.81M
Capital Expenditures	$89.68K	$37.64K	$97.64K
Free Cash Flow	-$17.16M	-$18.57M	-$53.91M
YoY Change	33.27%	93.61%	49.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022	CELC	Payments For Secondary Registration Statement Costs PaymentsForSecondaryRegistrationStatementCosts		usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2022	CELC	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable		usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss		usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss		usd
CY2022Q4	CELC	Miscellaneous Receivable MiscellaneousReceivable		usd
CY2023Q4	CELC	Prepaid On Research And Development PrepaidOnResearchAndDevelopment		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38207
CY2023	dei	Entity Registrant Name EntityRegistrantName	Celcuity Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2863566
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	16305 36th
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Avenue North
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 100
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Minneapolis
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55446
CY2023	dei	City Area Code CityAreaCode	(763)
CY2023	dei	Local Phone Number LocalPhoneNumber	392-0767
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	CELC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	191274949	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30453120	shares
CY2023	dei	Auditor Name AuditorName	Boulay LLP
CY2023	dei	Auditor Location AuditorLocation	Minneapolis, Minnesota
CY2023	dei	Auditor Firm AuditorFirmId	542
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30662774	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24571557	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	149919974	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	144015954	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10007849	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6603026	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	190590597	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	175190537	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	228782	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	260294	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400019	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246266	usd
CY2023Q4	us-gaap	Assets Assets	191219398	usd
CY2022Q4	us-gaap	Assets Assets	175697097	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5076699	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2627076	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2449	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	184950	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	191749	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8927094	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4060280	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14188743	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6881554	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	225922	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61002	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	37035411	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	34983074	usd
CY2023Q4	us-gaap	Liabilities Liabilities	51450076	usd
CY2022Q4	us-gaap	Liabilities Liabilities	41925630	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	854134	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	854134	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1120873	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1120873	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	854	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1121	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25506012	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25506012	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21667250	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21667250	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	25506	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	21667	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	299818965	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	230045566	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160076003	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96296887	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	139769322	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	133771467	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	191219398	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	175697097	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60594005	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35289548	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5636326	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4101543	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	66230331	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	39391091	usd
CY2023	us-gaap	Interest Expense InterestExpense	5326387	usd
CY2022	us-gaap	Interest Expense InterestExpense	2106111	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	7777602	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1127162	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2451215	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-978949	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63779116	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40370040	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-63779116	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-40370040	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.69
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.69
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.64
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.64
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23679472	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23679472	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15418543	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15418543	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	68710477	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	4638205	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	171710	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	152412	usd
CY2022	CELC	Stock Issued During Period Value Issuance Of Common And Preferred Stock Upon Closing Of Private Placement Offering StockIssuedDuringPeriodValueIssuanceOfCommonAndPreferredStockUponClosingOfPrivatePlacementOffering	100000000	usd
CY2022	CELC	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance With Private Placement Offering AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering	4316534	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5175000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	389763	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-40370040	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	133771467	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	202845	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	388522	usd
CY2023	CELC	Exercise Of Common Stock Warrants ExerciseOfCommonStockWarrants	-22505	usd
CY2023	CELC	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance With Private Placement Offering AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering	7486	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15000251	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	614205	usd
CY2023	CELC	Additional Paid In Capital Pre Funded Warrant Issued AdditionalPaidInCapitalPreFundedWarrantIssued	50000000	usd
CY2023	CELC	Issuance Costs Associated With Prefunded Warrants IssuanceCostsAssociatedWithPrefundedWarrants	-116895	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-63779116	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	139769322	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	139769322	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-63779116	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-40370040	usd
CY2023	us-gaap	Depreciation Depreciation	142772	usd
CY2022	us-gaap	Depreciation Depreciation	210918	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4901434	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4638205	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	241752	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	395757	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	1810584	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	455074	usd
CY2023	CELC	Noncash Operating Lease Net NoncashOperatingLeaseNet	4368	usd
CY2022	CELC	Noncash Operating Lease Net NoncashOperatingLeaseNet	-3243	usd
CY2023	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	993457	usd
CY2022	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	142928	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3438018	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	5526381	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2430614	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1077080	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4866814	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3257387	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53812253	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36008171	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	309614521	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	314525084	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	143873026	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	97644	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	158768	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5008207	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-144031794	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	22505	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	388522	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	152412	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	202845	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	171710	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	95721786	usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	19509037	usd
CY2023	CELC	Proceeds From An Atm Offering Net Of Commision And Offering Cost ProceedsFromAnATMOfferingNetOfCommisionAndOfferingCost	14431186	usd
CY2022	CELC	Proceeds From An Atm Offering Net Of Commision And Offering Cost ProceedsFromAnATMOfferingNetOfCommisionAndOfferingCost	4776046	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	49917589	usd
CY2023	CELC	Payments For Secondary Registration Statement Costs PaymentsForSecondaryRegistrationStatementCosts	45805	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2716	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2449	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5850	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	64911677	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120325141	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	6091217	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-59714824	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24571557	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	84286381	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30662774	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24571557	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3274051	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1255280	usd
CY2023	CELC	Deferred Financing Costs And Offering And Registration Statement Costs Included In Accounts Payable DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable	56414	usd
CY2022	CELC	Deferred Financing Costs And Offering And Registration Statement Costs Included In Accounts Payable DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable	51020	usd
CY2023	CELC	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	13615	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_znfnLH1JIK65" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zzsN638AO2Ib">Accounting Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be significant. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	30662774	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	24571557	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	149919974	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	144015954	usd
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	33195	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zPxR9dHpCnWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_zeCOVw2yHiE2">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval for gedatolisib and its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60594005	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35289548	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30662774	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	149919974	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18622423	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20454691	shares
CY2023Q4	CELC	Prefunded Warrant Shares PrefundedWarrantShares	5747787	shares
CY2022Q3	CELC	Deemed Dividend DeemedDividend	272000	usd
CY2022	CELC	Increased Net Loss Per Share Basic IncreasedNetLossPerShareBasic	0.02
CY2022	CELC	Increased Net Loss Per Share Diluted IncreasedNetLossPerShareDiluted	0.02
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	149919974	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	30995	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	149950969	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	144015954	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	71156	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	144087110	usd
CY2023Q4	CELC	Prepaid Clinical Trial PrepaidClinicalTrial	8763150	usd
CY2022Q4	CELC	Prepaid Clinical Trial PrepaidClinicalTrial	5656737	usd
CY2023Q4	CELC	Miscellaneous Receivable MiscellaneousReceivable	805882	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	281364	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	351073	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	157453	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	173416	usd
CY2022Q4	CELC	Prepaid On Research And Development PrepaidOnResearchAndDevelopment	421800	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10007849	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6603026	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2090772	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1979512	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1861990	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1719218	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	228782	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	260294	usd
CY2023	us-gaap	Depreciation Depreciation	142772	usd
CY2022	us-gaap	Depreciation Depreciation	210918	usd
CY2023Q4	CELC	Accrued Clinical Trial Expense AccruedClinicalTrialExpense	6464772	usd
CY2022Q4	CELC	Accrued Clinical Trial Expense AccruedClinicalTrialExpense	2246573	usd
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1763316	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	929216	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	641512	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	845524	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	57494	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	38967	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8927094	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4060280	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400019	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	410872	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	184950	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	225922	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	213537	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	220389	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	74170	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	508096	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	97224	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	410872	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	212238	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	197767	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2411	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5786	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	39	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	101957	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	81077	usd
CY2023	us-gaap	Lease Cost LeaseCost	316610	usd
CY2022	us-gaap	Lease Cost LeaseCost	284669	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	308914	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	282086	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	39	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2449	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5850	usd
CY2023	CELC	Cash Paid For Operating And Finance Leases CashPaidForOperatingAndFinanceLeases	311367	usd
CY2022	CELC	Cash Paid For Operating And Finance Leases CashPaidForOperatingAndFinanceLeases	287975	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	2100000	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21667250	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1120873	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25506012	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	854134	shares
CY2023	us-gaap	Dividends Dividends	0	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13011520	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2025-09-19
CY2022Q3	CELC	Estimated Incremental Fair Value Of Warrants EstimatedIncrementalFairValueOfWarrants	271988	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0341	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0486	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0168	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0422	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.771	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.798	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.762	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.796	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	CELC	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognized Next Twelve Months EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths	4075020	usd
CY2023Q4	CELC	Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Two Year EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear	2770901	usd
CY2023Q4	CELC	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognizedwithin Three Years EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears	1819779	usd
CY2023Q4	CELC	Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Four Years EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears	906379	usd
CY2023Q4	CELC	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost To Be Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized	9572079	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4901434	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4638205	usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	100000000	usd
CY2022Q3	CELC	Prepayment Fee Percentage PrepaymentFeePercentage	0.030	pure
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	346000	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	35000000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	35000000	usd
CY2023Q4	CELC	Payment In Kind Interest Debt PaymentInKindInterestDebt	2565660	usd
CY2022Q4	CELC	Payment In Kind Interest Debt PaymentInKindInterestDebt	755075	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	480810	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	707001	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	49439	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	65000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	37035411	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	34983074	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	14087122	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	18782830	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4695708	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	37565660	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13394000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8478000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-82000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-64000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13542000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9543000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	550000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1347000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	484000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	207000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	103000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2141000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1419000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	393000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	364000	usd
CY2023Q4	CELC	Deferred Tax Assets Rightofuse Assets DeferredTaxAssetsRightofuseAssets	-85000	usd
CY2022Q4	CELC	Deferred Tax Assets Rightofuse Assets DeferredTaxAssetsRightofuseAssets	-52000	usd
CY2023Q4	CELC	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	-87000	usd
CY2022Q4	CELC	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	-53000	usd
CY2023Q4	CELC	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Irc174 Expenditures DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures	13900000	usd
CY2022Q4	CELC	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Irc174 Expenditures DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures	3326000	usd
CY2023Q4	CELC	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures	11029000	usd
CY2022Q4	CELC	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures	10333000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8461000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7045000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36133000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22591000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	25900000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	700000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-011549-index-headers.html	Edgar Link	pending
0001493152-24-011549-index.html	Edgar Link	pending
0001493152-24-011549.txt	Edgar Link	pending
0001493152-24-011549-xbrl.zip	Edgar Link	pending
celc-20231231.xsd	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-2.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
celc-20231231_lab.xml	Edgar Link	unprocessable
celc-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
celc-20231231_def.xml	Edgar Link	unprocessable
celc-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELC
Celcuity Inc. Stock $celc

2024 Q1 Form 10-K Financial Statement

#000149315224011549 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC Celcuity Inc. Stock $celc

2024 Q1 Form 10-K Financial Statement

#000149315224011549 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC
Celcuity Inc. Stock $celc